Last reviewed · How we verify
NCT07161986
Mapping And Preventing Relapse Risk in Polydrug Users
NA trial testing Mindfullness based Sobriety (MBS) in Drug Addiction in 130 participants. Completed in 24 August 2025.
15 July 2025
Quick facts
| Lead sponsor | Institute of Psychology, Chinese Academy of Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 130 |
| Start date | 24 June 2025 |
| Primary completion | 15 July 2025 |
| Estimated completion | 24 August 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Mindfullness based Sobriety (MBS)
Conditions studied
- Drug Addiction — all drugs for Drug Addiction →
- Polysubstance Addiction — all drugs for Polysubstance Addiction →
Sponsor
Institute of Psychology, Chinese Academy of Sciences
Who can join
Adults 18 to 85, any sex, with Drug Addiction or Polysubstance Addiction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Interventional two-arm comparative study will evaluate whether a mindfulness-based strategy (MBS) improves outcomes for adults with substance use disorders (polydrug users) compared with treatment-as-usual (TAU). The primary question is whether MBS lowers cravings and reduces relapse risk relative to TAU; secondary aims include improvements in emotion regulation, coping, depressive/anxiety symptoms, mindfulness, and motivation to change. The design includes two arms (MBS vs TAU) with baseline and post-intervention assessments; adherence within the MBS arm will also be examined (e.g., high- vs low-adherence) to test whether greater adherence yields better primary and secondary outcomes than TAU. Primary outcomes are craving and relapse risk; secondary outcomes are emotion regulation, coping, depressive and anxiety symptoms, mindfulness, and motivation to change. Hypotheses predict that MBS will reduce cravings and depressive/anxiety symptoms and improve mindfulness and emotion regulation as compared to TAU; that psychological network structure will differ by relapse-risk level and by adherence subgroup; and that motivation to change will mediate MBS effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07161986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug Addiction
Currently open trials in the same condition.
- NCT07033728 — The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals · recruiting
- NCT05534815 — Long-Term Treatment of Opioid Use Disorder · NA · recruiting
- NCT03745339 — Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder · recruiting
Other Institute of Psychology, Chinese Academy of Sciences trials
Trials by the same sponsor.
- NCT06843824 — A Graphene Far-infrared Intervention Study of Cognitive Status in Older Adults · NA · completed
- NCT06346496 — Young People Aged 18-25 With Depression or Anxiety Mood Participate in an LLM-based Digital Dialogue Intervention Study · NA · completed
- NCT06181747 — Development of Attention and Its Relationship With Emotions in Children and Adolescents · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07161986 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Psychology, Chinese Academy of Sciences
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07161986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing